Fosun Pharma (02196) proposes to spin off Fosun Anticor and list it independently on the main board of the Hong Kong Stock Exchange.

The CITIC Financial News APP reported that Fosun Pharma (02196) announced that the company and its controlling shareholder, Fosun International Limited, have jointly applied to the Hong Kong Stock Exchange for approval to seek advice on a proposed spin-off listing, and the Hong Kong Stock Exchange has confirmed that the company and Fosun International are eligible for the proposed spin-off listing. On June 26, 2026, Fosun Antec Gold has submitted an application for listing to the Hong Kong Stock Exchange through its joint sponsors, to apply for the listing of Fosun Antec Gold H shares on the main board of the Hong Kong Stock Exchange and to be approved for trading.